| Literature DB >> 33800996 |
Ning Xu1,2,3, Miao Li2, Xiaohui Ai1,3,4, Zhoumeng Lin2.
Abstract
This study aimed to examine the pharmacokinetics of doxycycline (DC) in yellow catfish (Pelteobagrus fulvidraco) and to calculate related pharmacokinetic-pharmacodynamic (PK/PD) parameters of DC against Edwardsiella ictaluri. The minimum inhibitory concentration of DC against E. ictaluri was determined to be 500 µg/L. As the increase of oral dose from 10 to 40 mg/kg, the area under the concentration vs. time curve from 0 to 96 h (AUC0-96) values were considerably increased in gill, kidney, muscle and skin, and plasma, except in liver. Cmax values exhibited a similar dose-dependent increase trend in plasma and tissues except in liver, but other PK parameters had no apparent dose-dependence. The PK/PD parameter of the ratio of AUC0-96 to minimum inhibitory concentration (AUC0-96h/MIC) was markedly increased in plasma and tissues dose-dependently except in liver, but %T > MIC values were increased only moderately at some dose groups. After receiving the same dose with disparate time intervals from 96 to 12 h, the AUC0-96h/MIC was distinctly increased in plasma and tissues, but the %T > MIC had a decreasing trend. When administering 20 mg/kg with a time interval of 96 h, the AUC0-96h/MIC values were consistently >173.03 h and the %T > MIC values were above 99.47% in plasma and all tissues. These results suggest that administration of DC at 20 mg/kg every 96 h is a preferable regimen in yellow catfish.Entities:
Keywords: Edwardsiella ictaluri; doxycycline; pharmacokinetics; pharmacokinetic–pharmacodynamic (PK/PD) parameters; yellow catfish
Year: 2021 PMID: 33800996 PMCID: PMC8004065 DOI: 10.3390/antibiotics10030329
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Accuracy and precision of the method for doxycycline in fortified muscle and skin, liver, kidney, gill, and plasma samples of yellow catfish (Pelteobagrus fulvidraco).
| Tissues or Plasma | Spiked Level (µg/kg or µg/L) | Recovery (%) | Within-Day RSD (%) | Between-Day RSD (%) |
|---|---|---|---|---|
| Muscle and Skin | 50 | 77.3 | 4.4 | 5.1 |
| 500 | 83.7 | 3.8 | 4.6 | |
| 5000 | 80.2 | 4.7 | 5.8 | |
| Liver | 50 | 71.4 | 3.1 | 4.9 |
| 500 | 72.7 | 4.0 | 6.2 | |
| 5000 | 67.2 | 4.3 | 5.8 | |
| Kidney | 50 | 68.2 | 5.2 | 7.3 |
| 500 | 71.7 | 2.7 | 4.5 | |
| 5000 | 79.7 | 2.2 | 3.7 | |
| Gill | 50 | 80.3 | 3.5 | 5.5 |
| 500 | 81.7 | 2.8 | 4.1 | |
| 5000 | 72.6 | 3.7 | 5.6 | |
| Plasma | 50 | 82.7 | 4.5 | 5.7 |
| 500 | 82.5 | 3.9 | 6.3 | |
| 5000 | 77.2 | 4.7 | 6.1 |
RSD: Relative standard deviation.
Figure 1Semi-logarithmic plots of plasma and tissue concentration-time profiles of doxycycline in yellow catfish (Pelteobagrus fulvidraco) following an oral dose at 10 (A,B), 20 (C,D), or 40 mg/kg (E,F) at 24 °C. A, C, and E: For all sampling time points; B, D, and F: For a part of the sampling points from 0.083 to 12 h. Sample size: n = 6.
The pharmacokinetic parameters of doxycycline in gill, kidney, liver, muscle and skin, and plasma of yellow catfish (Pelteobagrus fulvidraco) after a single oral dose of 10, 20, and 40 mg/kg, respectively.
| Parameters | Unit | Gill | Kidney | Liver | Muscle and Skin | Plasma | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | 20 | 40 | 10 | 20 | 40 | 10 | 20 | 40 | 10 | 20 | 40 | 10 | 20 | 40 | ||
| λz | 1/h | 0.012 | 0.043 | 0.029 | 0.015 | 0.023 | 0.005 | 0.005 | 0.042 | 0.021 | 0.008 | 0.008 | 0.005 | 0.007 | 0.009 | 0.014 |
| T1/2 λz | h | 56.55 | 16.27 | 23.53 | 45.15 | 29.60 | 143.26 | 142.52 | 16.49 | 32.6 | 90.28 | 82.31 | 147.18 | 106.38 | 80.81 | 51.34 |
| Tmax | h | 0.50 | 0.50 | 0.50 | 1.00 | 0.50 | 2.00 | 1.00 | 24.00 | 1.00 | 6.00 | 4.00 | 12.00 | 6.00 | 4.00 | 12.00 |
| Cmax | mg/kg (L) | 0.66 | 120.74 | 151.94 | 1.03 | 11.64 | 15.40 | 1.08 | 34.81 | 24.95 | 0.18 | 2.30 | 2.84 | 0.44 | 4.67 | 6.99 |
| AUC0–96 | h*mg/L | 44.69 | 708.96 | 1207.18 | 57.23 | 260.95 | 471.78 | 54.65 | 1615.75 | 790.04 | 15.22 | 86.52 | 126.48 | 27.86 | 192.10 | 223.56 |
| AUC_%extrap | % | 35.30 | 5.40 | 7.29 | 31.48 | 15.00 | 57.32 | 63.85 | 4.42 | 13.57 | 50.54 | 47.75 | 60.82 | 51.71 | 38.42 | 28.01 |
| Vz_F | L/kg | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 26.60 | 7.47 | 9.54 |
| Cl_F | L/h/kg | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 0.17 | 0.06 | 0.13 |
Notes: λz, the terminal rate constant; T1/2 λz, the terminal half-life; Tmax, the time to reach the peak concentration; Cmax, the peak concentration; AUC0–96, the area under concentration time curve from 0 to 96 h; AUC_%extrap, percentage of AUC from time 0 to infinity due to extrapolation from the last observed time point to infinity; Cl_F, the total body clearance per fraction of dose absorbed; Vz_F, the volume of distribution based on the terminal phase per fraction of dose absorbed; NA, not available or not applicable; *, a multiplication sign.
The pharmacokinetic–pharmacodynamic parameters of doxycycline in gill, kidney, liver, muscle and skin, and plasma of yellow catfish (Pelteobagrus fulvidraco) given an oral dose of 10, 20, and 40 mg/kg at administration intervals of 96, 24, and 12 h, respectively.
| Tissues and Plasma | Time Intervals (h) | Oral Doses (mg/kg) | |||||
|---|---|---|---|---|---|---|---|
| 10 | 20 | 40 | |||||
| AUC0–96/MIC (h) | %T ˃ MIC (%) | AUC0–96/MIC (h) | %T ˃ MIC (%) | AUC0–96/MIC (h) | %T ˃ MIC (%) | ||
| Gill | 96 | 89.37 | 43.99 | 1471.91 | 100.00 | 2414.36 | 100.00 |
| 24 | 234.19 | 35.78 | 5037.98 | 96.00 | 7744.17 | 100.00 | |
| 12 | 425.79 | 21.94 | 9768.54 | 100.00 | 14677.36 | 100.00 | |
| Kidney | 96 | 114.47 | 69.44 | 521.90 | 100.00 | 943.55 | 99.99 |
| 24 | 304.91 | 65.56 | 1433.19 | 96.00 | 2707.67 | 99.99 | |
| 12 | 555.15 | 34.85 | 2660.07 | 94.84 | 4990.22 | 63.72 | |
| Liver | 96 | 109.30 | 78.02 | 3231.50 | 99.98 | 1580.08 | 100.00 |
| 24 | 284.60 | 71.70 | 9277.55 | 96.00 | 4548.55 | 100.00 | |
| 12 | 516.17 | 34.03 | 17116.13 | 23.59 | 8467.98 | 60.95 | |
| Muscle and Skin | 96 | 30.43 | NA | 173.03 | 99.47 | 252.95 | 99.89 |
| 24 | 79.25 | NA | 479.16 | 96.00 | 666.29 | 95.56 | |
| 12 | 143.61 | NA | 878.61 | 43.24 | 1213.31 | 40.54 | |
| Plasma | 96 | 55.72 | NA | 384.21 | 99.90 | 447.12 | 99.94 |
| 24 | 146.31 | 25.95 | 1087.35 | 96.00 | 1331.33 | 99.94 | |
| 12 | 265.29 | 12.99 | 1999.88 | 35.16 | 2461.86 | 53.31 | |
Notes: AUC0–96/MIC, the ratio of AUC0–96 to minimum inhibitory concentration; %T ˃ MIC, the percentage of time profile of DC concentration more than minimum inhibitory concentration to total time; NA, not available or not applicable.